Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Keurig Dr Pepper Inc ha un obiettivo di prezzo di consenso pari a $35.77, stabilito in base alle ultime valutazioni degli analisti di 22. Le ultime 3 valutazioni degli analisti sono state rilasciate da Goldman Sachs, Wells Fargo y Barclays il octubre 2, 2025, septiembre 25, 2025 y septiembre 24, 2025. Con un obiettivo di prezzo medio di $29.33 tra le Goldman Sachs, Wells Fargo y Barclays, c'è un implicito 13.78% upside per Keurig Dr Pepper Inc da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
10/02/2025 | 12.49% | Goldman Sachs | $34 → $29 | Maintains | Neutral | |||
09/25/2025 | 28.01% | Wells Fargo | $40 → $33 | Maintains | Overweight | |||
09/24/2025 | 0.85% | Barclays | $39 → $26 | Downgrade | Overweight → Equal-Weight | |||
09/22/2025 | -6.91% | BNP Paribas | → $24 | Downgrade | Neutral → Underperform | |||
09/17/2025 | 35.76% | Piper Sandler | $40 → $35 | Maintains | Overweight | |||
09/16/2025 | 43.52% | Citigroup | $41 → $37 | Maintains | Buy | |||
08/27/2025 | 35.76% | UBS | $40 → $35 | Maintains | Buy | |||
08/26/2025 | 47.4% | Deutsche Bank | $40 → $38 | Maintains | Buy | |||
08/26/2025 | 16.37% | HSBC | $42 → $30 | Downgrade | Buy → Hold | |||
07/28/2025 | 51.28% | Barclays | $37 → $39 | Maintains | Overweight | |||
07/17/2025 | 47.4% | JP Morgan | $39 → $38 | Maintains | Overweight | |||
07/17/2025 | 55.16% | UBS | $42 → $40 | Maintains | Buy | |||
06/27/2025 | 43.52% | Barclays | $38 → $37 | Maintains | Overweight | |||
04/28/2025 | 47.4% | Barclays | $37 → $38 | Maintains | Overweight | |||
04/25/2025 | 62.92% | HSBC | $36 → $42 | Upgrade | Hold → Buy | |||
04/22/2025 | 62.92% | RBC Capital | $42 → $42 | Reiterates | Outperform → Outperform | |||
04/17/2025 | 62.92% | UBS | $40 → $42 | Maintains | Buy | |||
04/16/2025 | 55.16% | Argus Research | → $40 | Initiates | → Buy | |||
04/09/2025 | 55.16% | Piper Sandler | $35 → $40 | Upgrade | Neutral → Overweight | |||
04/01/2025 | 55.16% | Morgan Stanley | $38 → $40 | Upgrade | Equal-Weight → Overweight | |||
02/27/2025 | 51.28% | Barclays | $36 → $39 | Maintains | Overweight | |||
02/26/2025 | 55.16% | JP Morgan | $37 → $40 | Maintains | Overweight | |||
02/26/2025 | 47.4% | Morgan Stanley | $36 → $38 | Maintains | Equal-Weight | |||
01/17/2025 | 39.64% | Barclays | $39 → $36 | Maintains | Overweight | |||
01/16/2025 | 43.52% | UBS | $42 → $37 | Maintains | Buy | |||
01/08/2025 | 39.64% | TD Cowen | $39 → $36 | Maintains | Hold | |||
01/07/2025 | 55.16% | Wells Fargo | $42 → $40 | Maintains | Overweight | |||
01/07/2025 | 35.76% | Piper Sandler | → $35 | Initiates | → Neutral | |||
12/12/2024 | 51.28% | Deutsche Bank | $37 → $39 | Upgrade | Hold → Buy | |||
10/28/2024 | 51.28% | Barclays | $41 → $39 | Maintains | Overweight | |||
10/25/2024 | 62.92% | UBS | $43 → $42 | Maintains | Buy | |||
10/25/2024 | 55.16% | Citigroup | $43 → $40 | Maintains | Buy | |||
10/25/2024 | 62.92% | RBC Capital | $41 → $42 | Maintains | Outperform | |||
10/25/2024 | 59.04% | Jefferies | $42 → $41 | Maintains | Buy | |||
10/25/2024 | 55.16% | JP Morgan | $41 → $40 | Maintains | Overweight | |||
10/25/2024 | 62.92% | Wells Fargo | $43 → $42 | Maintains | Overweight | |||
10/16/2024 | 59.04% | JP Morgan | $38 → $41 | Maintains | Overweight | |||
10/11/2024 | 59.04% | Barclays | $37 → $41 | Maintains | Overweight | |||
10/07/2024 | 66.79% | UBS | $39 → $43 | Maintains | Buy | |||
09/26/2024 | 55.16% | TD Cowen | $35 → $40 | Maintains | Hold | |||
09/23/2024 | 43.52% | Deutsche Bank | $36 → $37 | Maintains | Hold | |||
09/23/2024 | 66.79% | Citigroup | $36 → $43 | Upgrade | Neutral → Buy | |||
07/26/2024 | 59.04% | RBC Capital | $41 → $41 | Reiterates | Outperform → Outperform | |||
07/19/2024 | 43.52% | Barclays | $38 → $37 | Maintains | Overweight | |||
07/12/2024 | 51.28% | UBS | $40 → $39 | Maintains | Buy | |||
07/10/2024 | 39.64% | JP Morgan | $37 → $36 | Maintains | Overweight | |||
06/24/2024 | 39.64% | Exane BNP Paribas | → $36 | Initiates | → Neutral | |||
06/17/2024 | 31.88% | Truist Securities | $27 → $34 | Upgrade | Sell → Hold | |||
06/10/2024 | 55.16% | UBS | $39 → $40 | Maintains | Buy | |||
06/05/2024 | 59.04% | Wells Fargo | $39 → $41 | Maintains | Overweight | |||
04/29/2024 | 47.4% | Barclays | $36 → $38 | Maintains | Overweight | |||
04/26/2024 | 35.76% | TD Cowen | $32 → $35 | Maintains | Hold | |||
04/12/2024 | 39.64% | Barclays | $32 → $36 | Maintains | Overweight | |||
03/27/2024 | 35.76% | Jefferies | $37 → $35 | Maintains | Buy | |||
03/12/2024 | 24.13% | Barclays | $34 → $32 | Maintains | Overweight | |||
02/26/2024 | 31.88% | Morgan Stanley | $37 → $34 | Maintains | Equal-Weight | |||
02/26/2024 | 35.76% | Wedbush | $37 → $35 | Maintains | Outperform | |||
02/23/2024 | 59.04% | RBC Capital | $42 → $41 | Maintains | Outperform | |||
02/23/2024 | 31.88% | Barclays | $37 → $34 | Maintains | Overweight | |||
01/16/2024 | 43.52% | Barclays | $36 → $37 | Maintains | Overweight | |||
01/03/2024 | 43.52% | Morgan Stanley | → $37 | Downgrade | Overweight → Equal-Weight | |||
12/22/2023 | 43.52% | HSBC | → $37 | Initiates | → Hold | |||
11/13/2023 | 51.28% | Jefferies | → $39 | Initiates | → Buy | |||
10/30/2023 | 39.64% | Barclays | $34 → $36 | Maintains | Overweight | |||
10/27/2023 | 43.52% | Morgan Stanley | $39 → $37 | Maintains | Overweight | |||
10/12/2023 | 31.88% | Barclays | $40 → $34 | Maintains | Overweight | |||
10/12/2023 | 43.52% | Bernstein | $40 → $37 | Maintains | Outperform | |||
10/11/2023 | 28.01% | Citigroup | $37 → $33 | Maintains | Neutral | |||
08/16/2023 | 62.92% | UBS | $37 → $42 | Upgrade | Neutral → Buy | |||
07/28/2023 | 55.16% | Barclays | $37 → $40 | Maintains | Overweight | |||
07/11/2023 | 43.52% | Wedbush | $40 → $37 | Maintains | Outperform | |||
07/11/2023 | 35.76% | Citigroup | $37 → $35 | Maintains | Neutral | |||
07/06/2023 | 43.52% | Morgan Stanley | → $37 | Upgrade | Equal-Weight → Overweight | |||
05/01/2023 | 62.92% | RBC Capital | → $42 | Reiterates | → Outperform | |||
05/01/2023 | 43.52% | Barclays | $42 → $37 | Maintains | Overweight | |||
04/28/2023 | 55.16% | Wedbush | $43 → $40 | Maintains | Outperform | |||
04/28/2023 | 43.52% | Barclays | $42 → $37 | Maintains | Overweight | |||
04/18/2023 | 59.04% | JP Morgan | $40 → $41 | Maintains | Overweight | |||
04/14/2023 | 62.92% | Barclays | $40 → $42 | Maintains | Overweight | |||
03/20/2023 | 39.64% | Deutsche Bank | $38 → $36 | Maintains | Hold | |||
02/27/2023 | 55.16% | Barclays | $45 → $40 | Maintains | Overweight | |||
02/17/2023 | 43.52% | Citigroup | → $37 | Initiates | → Neutral | |||
01/26/2023 | 59.04% | JP Morgan | $40 → $41 | Maintains | Overweight | |||
01/03/2023 | 55.16% | Wells Fargo | $42 → $40 | Maintains | Overweight | |||
12/06/2022 | 51.28% | Deutsche Bank | $38 → $39 | Maintains | Hold | |||
10/31/2022 | 74.55% | Barclays | $41 → $45 | Maintains | Overweight | |||
10/31/2022 | 16.37% | Truist Securities | → $30 | Downgrade | Hold → Sell | |||
10/28/2022 | 62.92% | Wells Fargo | $41 → $42 | Maintains | Overweight | |||
10/17/2022 | 47.4% | Deutsche Bank | $37 → $38 | Maintains | Hold | |||
10/11/2022 | 66.79% | Wedbush | → $43 | Initiates | → Outperform | |||
10/03/2022 | 59.04% | Wells Fargo | $43 → $41 | Maintains | Overweight |
El último precio objetivo de Keurig Dr Pepper (NASDAQ:KDP) fue comunicado por Goldman Sachs el octubre 2, 2025. La firma de analistas fijó un precio objetivo para $29.00 que espera KDP a rise dentro de 12 meses (un posible 12.49% upside). 39 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Keurig Dr Pepper (NASDAQ:KDP) fue proporcionada por Goldman Sachs, y Keurig Dr Pepper mantuvo su neutral calificación.
La última revisión al alza de Keurig Dr Pepper Inc se produjo en abril 25, 2025, cuando HSBC elevó su precio objetivo a $42. HSBC anteriormente tenía a hold para Keurig Dr Pepper Inc.
La última revisión a la baja de Keurig Dr Pepper Inc se produjo en septiembre 24, 2025, cuando Barclays cambió su precio objetivo de $39 a $26 para Keurig Dr Pepper Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Keurig Dr Pepper, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Keurig Dr Pepper se registró el octubre 2, 2025, por lo que la próxima calificación estará disponible en torno al octubre 2, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Keurig Dr Pepper (KDP) fue un mantuvo con un precio objetivo de $34.00 a $29.00. El precio actual al que cotiza Keurig Dr Pepper (KDP) es de $25.78, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.